News

Biomednewsbreaks - Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Preclinical Data For SP-26 Ketamine Implant
Silo Pharma (NASDAQ: SILO) today announced favorable preclinical results for SP-26, its novel extended-release ketamine implant aimed at treating fib ...
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE ...
EXCLUSIVE: Silo Pharma's Investigational Ketamine Implant Hits All Endpoints In Pain Study In Animal Models
Silo Pharma reported positive preclinical results for its ketamine-based implant SP-26, designed to treat chronic pain and ...
Investornewsbreaks Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application For Alzheimer's Drug SPC-14
Silo Pharma (NASDAQ: SILO) announced the filing of a patent application with the U.S. Patent and Trademark Office for SPC-14, a novel intranasal comp ...
Business Observer3d
Sarasota company applies for Alzheimer's drug patent
A Sarasota biopharmaceutical company is applying for a patent for an Alzheimer’s drug. Silo Pharma, based on North Washington ...
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel ...
Silo Pharma files to sell 4.72M shares of common stock, warrants
H.C. Wainwright & Co. is acting as manager. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart ...